(Q51164170)

31 March 2018

title

Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain. (English)

1 reference

31 March 2018

1 reference

Josep Darbà

1

1 reference

31 March 2018

Gabriela Restovic

series ordinal

2

1 reference

31 March 2018

Lisette Kaskens

series ordinal

3

1 reference

31 March 2018

Tuy de Agustín

series ordinal

4

1 reference

31 March 2018

publication date

18 May 2011

1 reference

31 March 2018

The Journal of Clinical Pharmacology

published in

1 reference

31 March 2018

volume

52

1 reference

31 March 2018

issue

4

1 reference

31 March 2018

page(s)

566-575

1 reference

31 March 2018

Clinical uses of intravenous immunoglobulin.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Intravenous immunoglobulin: regulatory perspectives on use and supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Intravenous immune globulins: an update for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Economic assessment of different modalities of immunoglobulin replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Pharmacoeconomics of immunoglobulins in primary immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

Cost of illness studies: what is good about them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011399575

21 January 2018

Identifiers

DOI

10.1177/0091270011399575

1 reference

31 March 2018

1 reference

31 March 2018